Skye Bioscience, Inc. is a biopharmaceutical firm focused on the discovery, development, and commercialization of cannabinoid-based therapeutics, primarily targeting various ophthalmic conditions. The company's leading drug candidate, SBI-100, is currently undergoing Phase I clinical trials for the treatment of glaucoma and ocular hypertension. In addition, Skye Bioscience is developing SBI-200, which is in preclinical stages, to manage and treat a spectrum of eye diseases such as uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy.